Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Zai Lab's NDA for PARP Inhibitor Accepted for China Review

publication date: Dec 12, 2018

Zai Lab of Shanghai announced that the China National Medical Products Administration (NMPA) accepted its NDA for Zejula (niraparib), a novel Category 1 PARP1/2 drug -- the first Zai NDA submission accepted in China. The candidate is indicated for maintenance treatment of patients with recurrent ovarian and fallopian tube cancer who are in a complete or partial response to platinum-based chemotherapy. According to Zai, Zejula is a potent, highly selective PARP1/2 inhibitor that does not require prior testing for BRCA mutation. More details....

Stock Symbol: (NSDQ: ZLAB)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.